Basel Medical Group Ltd (BMGL) Aandelenanalyse

Bedrijfsoverzicht

Basel Medical Group Ltd is a healthcare provider that delivers specialized medical care services within Singapore, focusing primarily on orthopedic treatments. The company's operational scope includes general and subspecialized orthopedic procedures, encompassing trauma and sports medicine interventions such as knee and hip replacements, spine surgery, and foot and ankle operations. Operating within the Healthcare sector and specifically the Medical Care Facilities industry, the firm serves patients requiring minimally invasive orthopedic prosthetics and surgical solutions. As a small-cap entity with a market capitalization of $11.07M and an annual revenue of $11.35M, the company employs 82 individuals to execute its service model. These valuation and revenue figures indicate that the organization operates on a modest scale relative to large-cap healthcare peers, suggesting a business model that likely relies on volume or specific niche procedures to generate cash flow rather than broad market dominance.

Financiële gezondheid

The company reported revenue of $11.35M over the trailing twelve months, yet it recorded a net income of $-10,635,677 and an EBITDA of $-2,033,239. The substantial divergence between the positive revenue figure and the significant net loss reveals a cost structure where operating expenses, including cost of goods sold and general administrative costs, vastly exceed the gross profit generated. Despite the reported net loss and negative EBITDA, the entity maintains a free cash flow of $3.03M, which provides a crucial buffer for financial flexibility by allowing the company to fund operations without immediate external financing. The gross margin stands at 21.2%, indicating that the company retains roughly one-fifth of its revenue after direct costs, while the operating margin of -24.9% and profit margin of -93.7% highlight severe operational inefficiencies or high fixed costs relative to sales. In terms of liquidity and leverage, the company holds $9.82M in cash against $6.53M in debt, resulting in a debt-to-equity ratio of 120.04 which suggests a highly leveraged balance sheet. The current ratio of 1.31 indicates that the company possesses sufficient current assets to cover its short-term liabilities, though the margin is relatively tight given the negative operating income. Return on equity is recorded at -163.6% and return on assets at -7.6%, metrics that collectively reveal that management has not yet generated returns sufficient to cover the capital invested or the assets employed in the business.

Waarderingsbeoordeling

The trailing P/E ratio is listed as N/A and the forward P/E is also N/A due to the company's consistent net losses, which implies that traditional earnings-based valuation metrics are currently inapplicable for assessing the stock's trajectory. Instead, the market values the company at a price-to-book ratio of 2.60, indicating that the stock trades at a premium of 160% above its book value despite the absence of current earnings. Alternative valuation metrics such as the price-to-sales ratio of 0.97 and an EV/EBITDA of -3.83 provide context for the company's valuation relative to its sales volume and enterprise value. The stock has experienced significant volatility, trading between a 52-week low of $0.49 and a 52-week high of $9.40. Given the current market price dynamics implied by the wide range, the stock is trading in a zone that reflects the high uncertainty associated with a loss-making healthcare provider attempting to turn around its operational performance. The beta value is listed as N/A, meaning that historical volatility data relative to the broader market is unavailable for this specific ticker.

Growth & Income

Revenue growth year-over-year is recorded at 27.3%, demonstrating a robust expansion in top-line sales, whereas earnings growth is N/A due to the continued net losses. The disparity between strong revenue growth and negative earnings growth implies that the company is reinvesting heavily in operations or struggling with cost containment while scaling its service offerings. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available cash flow is retained within the business to fund growth initiatives rather than being distributed to shareholders. Since the firm is not a dividend payer, the overall growth and income profile is characterized by capital appreciation potential derived from future operational profitability rather than current income generation.